BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05688852 (VTX958 in Crohn Disease): BVCT ex-ante prediction vs. reported outcome

On 23 Apr 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 29 Jul 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05688852
Acronym
Harmony-CD
Drug Name
VTX958
Drug MoA
oral selective allosteric TYK2 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Crohn Disease
Human Patients
132
Sponsor
Ventyx Biosciences
Phase
Phase 2

Prediction of , index 1257

Prospective Prediction
Prediction Index
1257
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
97 days in advance
Readout Data Interpretation
primary endpoint in CDAI score not met.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease
Phase
Phase 2
Status
Terminated
Enrollment
107
Lead sponsor
Ventyx Biosciences, Inc
Conditions
Crohn Disease
Interventions
DRUG: VTX958; DRUG: VTX958; DRUG: VTX958 Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-01-25
Primary completion
2024-06-27
Completion
2024-12-20
Primary outcomes
  • Change in mean Crohn's disease Activity Index (CDAI) score from baseline to week 12 (During screening to week 12)

NCT05688852 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials